Hypertension Unit, Centre Hospitalier Universitaire de Québec, Québec, Canada.
Clin Exp Hypertens. 2013;35(1):50-60. doi: 10.3109/10641963.2012.690468. Epub 2012 Aug 6.
The aim of this review was to compare telmisartan and valsartan in the treatment of hypertension. PubMed searches were conducted to identify randomized trials (n = 14) comparing the two agents, alone or combined with hydrochlorothiazide. With one exception, all studies with blood pressure reduction as primary endpoint showed significantly greater reductions with telmisartan than with valsartan. Other studies showed that telmisartan was associated with greater improvements in metabolic measures and inflammatory markers than valsartan. These findings suggest that pharmacologic differences between telmisartan and valsartan may translate into clinically relevant differences between the two drugs in the management of hypertension.
本综述的目的是比较替米沙坦和缬沙坦在高血压治疗中的作用。通过 PubMed 检索,我们共找到了 14 项比较这两种药物的随机试验(n=14),这些试验单独或联合氢氯噻嗪进行。除了一项研究外,所有以降低血压作为主要终点的研究均显示替米沙坦降压作用明显优于缬沙坦。其他研究还表明,与缬沙坦相比,替米沙坦能更显著地改善代谢指标和炎症标志物。这些发现提示替米沙坦和缬沙坦之间的药理学差异可能会转化为两种药物在高血压治疗中临床相关的差异。